Pharmacokinetics and pharmacodynamic interaction of bergamottin with atorvastatin in rats

References

• Akiyoshi T, Uchiyama M, Inada R, Imaoka A, Ohtani H. 2022. Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activity. Drug Metab Pharmacokinet. 42:100429.
   PubMedGoogle Scholar
• Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, Takamura T, Kaneko S, Fujimura A. 2005. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 60(5):494–497.
   PubMed Web of Science ®Google Scholar
• Bahmani M, Mirhoseini M, Shirzad H, Sedighi M, Shahinfard N, Rafieian-Kopaei M. 2015. A review on promising natural agents effective on hyperlipidemia. J Evid Based Complementary Altern Med. 20(3):228–238.
   PubMedGoogle Scholar
• Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B. 2000. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 30(12):1131–1152.
   PubMed Web of Science ®Google Scholar
• Capomolla AS, Janda E, Paone S, Parafati M, Sawicki T, Mollace R, Ragusa S, Mollace V. 2019. Atherogenic index reduction and weight loss in metabolic syndrome patients treated with a novel pectin-enriched formulation of bergamot polyphenols. Nutrients. 11(6):1271.
   PubMed Web of Science ®Google Scholar
• Cheuka PM, Mayoka G, Mutai P, Chibale K. 2016. The role of natural products in drug discovery and development against neglected tropical diseases. Molecules. 22(1):58.
   PubMed Web of Science ®Google Scholar
• Chora JR, Bourbon M. 2021. Pharmacogenomics of statins and familial hypercholesterolemia. Curr Opin Lipidol. 32(2):96–102.
   PubMedGoogle Scholar
• Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, et al. 2016. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. 2008. Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J Agric Food Chem. 56(12):4840–4845.
   PubMed Web of Science ®Google Scholar
• El-Tantawy WH, Temraz A. 2019. Natural products for controlling hyperlipidemia: review. Arch Physiol Biochem. 125(2):128–135.
   PubMed Web of Science ®Google Scholar
• Famularo G, Sarrecchia C. 2021. Atorvastatin-associated gynecomastia. Ann Pharmacother. 55(10):1300–1301.
   PubMedGoogle Scholar
• Fukazawa I, Uchida N, Uchida E, Yasuhara H. 2004. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol. 57(4):448–455.
   PubMedGoogle Scholar
• Gamble JT, Nakatsu K, Marks GS. 2002. Comparison of rat and human cytochrome P450 (CYP) sources of N-alkylprotoporphyrin IX. Formation after interaction with porphyrinogenic xenobiotics: studies with cDNA-expressed single CYP enzymes. Xenobiotica. 32(11):997–1006.
   PubMed Web of Science ®Google Scholar
• Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, et al. 2004. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther. 76(6):607–617.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. 2011. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 7(3):267–286.
   PubMed Web of Science ®Google Scholar
• Hirota T, Fujita Y, Ieiri I. 2020. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 16(9):809–822.
   PubMed Web of Science ®Google Scholar
• Hirota T, Ieiri I. 2015. Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 11(9):1435–1447.
   PubMed Web of Science ®Google Scholar
• Karr S. 2017. Epidemiology and management of hyperlipidemia. Am J Manag Care. 23(9 Suppl):S139–s48.
   PubMed Web of Science ®Google Scholar
• Ko JH, Nam D, Um JY, Jung SH, Ahn KS. 2018. Bergamottin inhibits adipogenesis in 3T3-L1 cells and weight regulation in diet-induced obese mice. Am J Chin Med. 46(3):601–615.
   PubMedGoogle Scholar
• Le Goff-Klein N, Klein L, Hérin M, Koffel JC, Ubeaud G. 2004. Inhibition of in-vitro simvastatin metabolism in rat liver microsomes by bergamottin, a component of grapefruit juice. J Pharm Pharmacol. 56(8):1007–1014.
   PubMedGoogle Scholar
• Lilja JJ, Kivistö KT, Neuvonen PJ. 1998. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 64(5):477–483.
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Kivistö KT, Neuvonen PJ. 1999. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 66(2):118–127.
   PubMed Web of Science ®Google Scholar
• Liu B, Tang Y, Song Z, Ge J. 2021. Polygonatum sibiricum F. Delaroche polysaccharide ameliorates HFD‑induced mouse obesity via regulation of lipid metabolism and inflammatory response. Mol Med Rep. 24(1):501.
   Google Scholar
• Liu Y, Zhang S, Jiang T, Tan R, Fu Y, Yang X, Gong B, Zou Y, Li W, Zheng J. 2021. Mechanistic study of bergamottin-induced inactivation of CYP2C9. Food Chem Toxicol. 153:112278.
   PubMed Web of Science ®Google Scholar
• Lv B, Xun T, Wu S, Zhan X, Rong Y, Zhang Q, Yang X. 2019. Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study. J South Med Univ. 039:337–343.
   Google Scholar
• Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, et al. 2018. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 39(27):2526–2539.
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, et al. 2019. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 39:e38–e81.
   PubMed Web of Science ®Google Scholar
• Noce A, Di Lauro M, Di Daniele F, Pietroboni Zaitseva A, Marrone G, Borboni P, Di Daniele N. 2021. Natural bioactive compounds useful in clinical management of metabolic syndrome. Nutrients. 13(2):630.
   PubMedGoogle Scholar
• Olguín-Reyes S, Camacho-Carranza R, Hernández-Ojeda S, Elinos-Baez M, Espinosa-Aguirre JJ. 2012. Bergamottin is a competitive inhibitor of CYP1A1 and is antimutagenic in the Ames test. Food Chem Toxicol. 50(9):3094–3099.
   PubMedGoogle Scholar
• Parvez MK, Rishi V. 2019. Herb-drug interactions and hepatotoxicity. Curr Drug Metab. 20(4):275–282.
   PubMed Web of Science ®Google Scholar
• Reddy P, Ellington D, Zhu Y, Zdrojewski I, Parent SJ, Harmatz JS, Derendorf H, Greenblatt DJ, Browne K Jr. 2011. Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol. 72(3):434–441.
   PubMed Web of Science ®Google Scholar
• Sama V, Pagilla B, Chiluka R, Alvala R, Pola RK, Mullangi R. 2019. Bioenhancing effects of naringin on atorvastatin. Admet Dmpk. 7(3):174–182.
   PubMedGoogle Scholar
• Stewart J, McCallin T, Martinez J, Chacko S, Yusuf S. 2020. Hyperlipidemia. Pediatr Rev. 41(8):393–402.
   PubMedGoogle Scholar
• Suzuki K, Taniyama K, Aoyama T, Watanabe Y. 2020. Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats. Xenobiotica. 50(4):401–407.
   PubMed Web of Science ®Google Scholar
• Thomas AB, Choudhary DC, Raje A, Nagrik SS. 2021. Pharmacokinetics and pharmacodynamic herb-drug interaction of piperine with atorvastatin in rats. J Chromatogr Sci. 59(4):371–380.
   PubMedGoogle Scholar
• Wang TJ, Lien AS, Chen JL, Lin CH, Yang YS, Yang SH. 2019. A randomized clinical efficacy trial of red yeast rice (Monascus pilosus) against hyperlipidemia. Am J Chin Med. 47(2):323–335.
   PubMed Web of Science ®Google Scholar
• Wen YH, Sahi J, Urda E, Kulkarni S, Rose K, Zheng X, Sinclair JF, Cai H, Strom SC, Kostrubsky VE. 2002. Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. Drug Metab Dispos. 30(9):977–984.
   PubMedGoogle Scholar
• Yan LL, Zhang WY, Wei XH, Yan L, Pan CS, Yu Y, Fan JY, Liu YY, Zhou H, Han JY, Yao XS. 2018. Gualou Xiebai decoction, a traditional Chinese medicine, prevents cardiac reperfusion injury of hyperlipidemia rat via energy modulation. Front Physiol. 9:296.
   PubMedGoogle Scholar
• Zarei L, Mahdavi Rad S, Abdollahzade Fard A. 2019. Co-administration of retinoic acid and atorvastatin mitigates high-fat diet induced renal damage in rats. Vet Res Forum. 10(2):133–138.
   PubMedGoogle Scholar
• Zsidó BZ, Balog M, Erős N, Poór M, Mohos V, Fliszár-Nyúl E, Hetényi C, Nagane M, Hideg K, Kálai T, et al. 2020. Synthesis of spin-labelled bergamottin: a potent CYP3A4 inhibitor with antiproliferative activity. Int J Mol Sci. 21(2):508.
   Web of Science ®Google Scholar